Pliant Therapeutics Inc (PLRX) Stock Price, Quote & News

Company Profile

Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonal...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 481 6770

Website: pliantrx.com

Address:

331 Oyster Point Boulevard, South San Francisco, United States

OfficialStocktwitsUser Feb. 24 at 11:53 PM

$PLRX RSI: 55.36, MACD: -0.0068 Vol: 0.06, MA20: 1.20, MA50: 1.24 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

WaterWings Feb. 24 at 10:34 PM

$PLRX This one is starting to get predictable, climb to 1.30ish by Friday and then drop back down to 1.20ish by Monday. Better than 5% but not quite 10% gains

1 · Reply

sandman7473 Feb. 24 at 8:56 PM

$PLRX RBC Capital Maintains Pliant Therapeutics(PLRX.US) With Hold Rating, Maintains Target Price $2

0 · Reply

THSSKS Feb. 24 at 9:07 AM

$GOSS might as well bankrupt the company now. No future with a couple hundred million in debt. This is why I only buy bioturds with huge cash piles like $PLRX BOLD FATE etccccc.

0 · Reply

sandman7473 Feb. 23 at 1:46 PM

$PLRX https://www.tradingview.com/news/globenewswire:86f9685af094b:0-pliant-therapeutics-to-participate-in-the-oppenheimer-healthcare-life-science-conference/

0 · Reply

Gunnar1 Feb. 21 at 11:43 AM

$PLRX Bigger picture, weekly chart: Green lines = area of support, red lines = area of resistance. Triple bottom since last April. This week we closed above EMA 5, let's hope that we'll have a run up this time as last July. Needs to break EMA10 and 20 for continuation and to go for GAP1. MACD and RSI are climbing up as well. We'll see...

0 · Reply

sandman7473 Feb. 20 at 3:01 AM

$PLRX volume increasing and closed above 50day. March is going to be 🔥 imo.

0 · Reply

JacobJones1 Feb. 19 at 8:09 PM

$PLRX good things coming here.

0 · Reply

Gunnar1 Feb. 19 at 9:26 AM

$PLRX Next step is to break 1.27$ and stay above.

0 · Reply

THSSKS Feb. 19 at 6:56 AM

$PLRX Good data could easily take this to $10. A sale possibly next month when poison pill expires can take this to $2.50-$3 ( Tang won’t overpay), garbage data and board recognizing it’s time for strategic alternatives could take this to $1.50-$2. Cash is acting as a cushion here. Limited downside imo

0 · Reply

Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration

Feb 23, 2026, 8:00 AM EST - 1 day ago

Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference

Dec 4, 2025, 1:53 PM EST - 2 months ago

Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors

MRK

$Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors$

Dec 4, 2025, 7:30 AM EST - 2 months ago

Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Dec 1, 2025, 8:30 AM EST - 3 months ago

Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference

Nov 6, 2025, 4:05 PM EST - 3 months ago

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 7 months ago

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Jun 27, 2025, 4:05 PM EDT - 8 months ago

Pliant Therapeutics Provides Update on BEACON-IPF

May 21, 2025, 4:03 PM EDT - 9 months ago

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

May 8, 2025, 4:05 PM EDT - 10 months ago

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 1, 2025, 4:05 PM EDT - 10 months ago

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

Apr 7, 2025, 4:05 PM EDT - 11 months ago

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

Apr 3, 2025, 12:22 PM EDT - 11 months ago

Pliant Therapeutics: An Activist On Deck

$Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors$

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Mar 13, 2025, 11:04 AM EDT - 1 year ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics

Mar 13, 2025, 7:20 AM EDT - 1 year ago

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

Mar 3, 2025, 4:05 PM EST - 1 year ago

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

Mar 3, 2025, 1:32 PM EST - 1 year ago

Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder

Mar 3, 2025, 9:27 AM EST - 1 year ago

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Mar 2, 2025, 11:00 AM EST - 1 year ago

The Schall Law Firm Invites Shareholders With Losses In Pliant Therapeutics, Inc. To Join A Securities Fraud Investigation

Feb 27, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Shareholders to Inquire about Securities Investigation

Feb 26, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Connect

Feb 25, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Reach Out

Feb 24, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Shareholders to Learn More About the Investigation

Feb 23, 2025, 10:00 AM EST - 1 year ago

Pliant Therapeutics, Inc. (PLRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 21, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Investors to Connect

Feb 20, 2025, 3:39 PM EST - 1 year ago

PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Feb 20, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Stockholders to Inquire about Securities Investigation

Feb 19, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Investors to Learn More About the Investigation

OfficialStocktwitsUser Feb. 24 at 11:53 PM

0 · Reply

WaterWings Feb. 24 at 10:34 PM

$PLRX This one is starting to get predictable, climb to 1.30ish by Friday and then drop back down to 1.20ish by Monday. Better than 5% but not quite 10% gains

1 · Reply

sandman7473 Feb. 24 at 8:56 PM

$PLRX RBC Capital Maintains Pliant Therapeutics(PLRX.US) With Hold Rating, Maintains Target Price $2

0 · Reply

THSSKS Feb. 24 at 9:07 AM

$GOSS might as well bankrupt the company now. No future with a couple hundred million in debt. This is why I only buy bioturds with huge cash piles like $PLRX BOLD FATE etccccc.

0 · Reply

sandman7473 Feb. 23 at 1:46 PM

$PLRX https://www.tradingview.com/news/globenewswire:86f9685af094b:0-pliant-therapeutics-to-participate-in-the-oppenheimer-healthcare-life-science-conference/

0 · Reply

Gunnar1 Feb. 21 at 11:43 AM

0 · Reply

sandman7473 Feb. 20 at 3:01 AM

$PLRX volume increasing and closed above 50day. March is going to be 🔥 imo.

0 · Reply

JacobJones1 Feb. 19 at 8:09 PM

$PLRX good things coming here.

0 · Reply

Gunnar1 Feb. 19 at 9:26 AM

$PLRX Next step is to break 1.27$ and stay above.

0 · Reply

THSSKS Feb. 19 at 6:56 AM

0 · Reply

NorthStarStats Feb. 19 at 2:18 AM

For anyone following along, I developed a Python-based statistical scanner to identify stocks with near-term institutional accumulation and upward price momentum. The market perked up a bit, but still very dangerous for the momentum trader. Stock picks from the scanner: $GPN Score 98.00, $PLRX Score 98.00, $AWK Score 95.00, $APA Score 71.00, $GRFS Score 70.00

0 · Reply

UnderPaid_ATC Feb. 18 at 9:51 PM

$PLRX sold the pop, buy back at 1.12

1 · Reply

SQUEAKSBANDIT Feb. 18 at 3:37 PM

$PLRX as much as i like this name long term, i must admit i flipped again something about those quick percentage gains

0 · Reply

MadHatterTrades74 Feb. 18 at 2:16 PM

$PLRX I only bought in because of point 72 assets position in Sept.2025 and now they apparently they gave up almost all their position.😡

2 · Reply

BillionerOfKing Feb. 18 at 1:42 AM

$PLRX Current Stock Price: $1.13 Contracts to trade: $1.0 PLRX Feb 20 2026 Call Entry: $0.32 Exit: $0.43 ROI: 32% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

MrTicker Feb. 17 at 8:43 PM

$PLRX Form SCHEDULE 13G/A PLIANT THERAPEUTICS, Filed by: Woodline Partners LP 10K WIZARD 2:22 PM ET 2/17/2026 http://archive.fast-edgar.com/20260217/A42FS2228222P2Z2222F22OF9PRVZ222L282 Filed on: February 17, 2026

1 · Reply

SQUEAKSBANDIT Feb. 17 at 5:54 PM

$PLRX i admit I flipped on the quick pop maybe too soon, maybe it has another leg lower

0 · Reply

MetatheoryMetrics Feb. 17 at 3:41 PM

$PLRX Pliant Therapeutics is a clinical-stage biotech developing therapies for fibrosis, with lead candidate bexotegrast in Phase 2b for IPF and PSC, and recent Phase 1 data for PLN-101095 showing anti-tumor activity in solid tumors . The company faces high cash burn and persistent losses, with projected negative EPS, though analysts see potential upside with a wide price target range . Recent trading has been volatile, with shares down on interim data announcements despite positive efficacy signals .

1 · Reply

THSSKS Feb. 17 at 9:09 AM

$PLRX Presentation was added to their site on 2/12/26. Hopefully this gets pumped into next data or just bought out for their assets https://ir.pliantrx.com/static-files/961ddac3-b132-470b-b9ea-a01dbc33447a

0 · Reply

SQUEAKSBANDIT Feb. 15 at 7:14 PM

$PLRX we are just a few ticks off the apr 9th panic low of 1.09 - 1.10 an uncommon bargain at these levels

0 · Reply

sandman7473 Feb. 15 at 12:20 AM

$PLRX centiva capital lp - 1m shares reported yesterday.

0 · Reply

SQUEAKSBANDIT Feb. 13 at 8:32 PM

$PLRX that 1.12 ask is awfully tasty

1 · Reply

Market Cap	75.58M
Revenue (ttm)	0.00
Net Income (ttm)	-210.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.15

Volume	357,200
Avg Vol	930,522
Day's Range	N/A - N/A
Shares Out	61.45M
Stochastic %K	74%
Beta	1.38
Analysts	Hold
Price Target	$3.00